Publication Details
Abstract
As far as women are concerned, autoimmune disorders pose an important threat to their health, with both gynecological and systemic manifestations. To examine autoimmune disorders, treatment modalities, and post-treatment outcomes in females with autoimmune disorders. Gynecological and systemic manifestations that occur during a 12-month follow-up are of interest. One hundred five female patients diagnosed with different autoimmune disorders were included in this cross-sectional study conducted in Al-Diwaniyah, Iraq, from April 2023 to April 2024. Baseline data were collected on various clinical characteristics, types of autoimmune diseases, and treatment modalities employed to treat the patients. Assessment of symptoms and quality of life was done for all patients through standardized questionnaires at baseline and at 1, 3, 7, and 12 months following treatment. Most of the cohort were women aged 20-40 years (52.4%), with the mean BMI being 24.5 ± 3.2 kg/m². Hypertension and asthma stood foremost among the comorbidities, being 23.8% and 17.1% prevalent, respectively. Of autoimmune disorders, the most common ones were rheumatoid arthritis, 43 (40.95), and lupus, 20 (19.0). Among gynecological symptoms were more irregular menstrual cycles (47.6%), whereas fatigue (66.7%) was the common systemic symptom. Response to treatment at 12 months yielded the most significant reduction in symptoms and improvement in quality of life. This study articulates the severe effects that autoimmune disorders pose on systemic and gynecological health in women. In this case, timely diagnosis and directed therapy lead to better outcomes and improved quality of life.